Chest
Original ResearchCystic FibrosisBronchiectasis and Pulmonary Exacerbations in Children and Young Adults With Cystic Fibrosis
Section snippets
Study Population
This institutional review board-approved, retrospective, single-center study used clinical data from patients with CF who were followed at the Sophia Children's Hospital Cystic Fibrosis Clinic in Rotterdam, The Netherlands. Inclusion criteria were: (1) confirmed CF diagnosis, (2) one or more routine biannual chest CT scans performed between March 2002 and March 2006 while clinically stable (CT scans performed for acute respiratory deterioration were not included in the current analysis), (3) at
Results
We identified 156 patients who had at least one chest CT scan during the study period. From this cohort, 41 patients were excluded for reasons outlined in Figure 1. Thus, 115 patients were included in the current analyses, with 55 contributing two scans and 60 contributing one scan for a total of 170 scans. Total person-years of follow-up was 335. The mean ± SD follow-up period was 23.6 ± 2.2 months after each CT scan. Spirometry was performed on the same day as CT scanning for 149 of 170
Discussion
The US Food and Drug Administration defines a surrogate end point as “a laboratory measurement or physical sign that is used in therapeutic trials as a substitute for a clinically meaningful endpoint that is a direct measure of how a patient feels, functions, or survives.”20 Surrogate end points, such as CT scan scores, generally are used as a substitute for true clinical efficacy measures, such as RTEs, when the clinical benefit may not be detectable in trials of reasonable cost, duration, or
Acknowledgments
Author contributions: Dr Loeve: contributed to the study design, CT scan scoring, statistical analysis, and writing of the manuscript.
Dr Gerbrands: contributed to the data collection, CT scan scoring, and critical reading of the manuscript.
Dr Hop: contributed to the study design, statistical analysis, and writing of the manuscript.
Dr Hartmann: contributed to the study design and critical reading of the manuscript.
Dr Rosenfeld: contributed to the study design and writing of the manuscript.
Dr
References (36)
- et al.
Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference
J Pediatr
(1994) Bronchiectasis
Radiol Clin North Am
(1998)- et al.
Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis
J Pediatr
(2001) - et al.
Defining a pulmonary exacerbation in cystic fibrosis
J Pediatr
(2001) - et al.
Influenza-associated cystic fibrosis pulmonary exacerbations
Chest
(2010) - et al.
High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests
J Pediatr
(2004) Biomarkers and surrogate markers: an FDA perspective
NeuroRx
(2004)- et al.
Structural airway abnormalities in infants and young children with cystic fibrosis
J Pediatr
(2004) An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all
Proc Am Thorac Soc
(2007)- et al.
Endpoints for clinical trials in young children with cystic fibrosis
Proc Am Thorac Soc
(2007)
Advancing outcome measures for the new era of drug development in cystic fibrosis
Proc Am Thorac Soc
Improving rate of decline of FEV1 in young adults with cystic fibrosis
Thorax
Detecting early structural lung damage in cystic fibrosis
Pediatr Pulmonol
Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis
Thorax
Imaging and clinical trials in cystic fibrosis
Proc Am Thorac Soc
Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis
Am J Respir Crit Care Med
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis
Pediatr Pulmonol
Survey of CT Practice in the UK. Part 3: Normalised Organ Doses for X-ray Computed Tomography Using Monte Carlo Techniques
Cited by (60)
Effect of Sex Differences on Computed Tomography Findings in Adults With Cystic Fibrosis: A Multicenter Study
2021, Archivos de BronconeumologiaRisk factors for progression of structural lung disease in school-age children with cystic fibrosis
2020, Journal of Cystic FibrosisCitation Excerpt :Chest CT is the gold standard for assessing structural lung disease (SLD) [2]. The most important and well-described structural lung pathology in patients with CF is bronchiectasis, which is associated with a reduced quality of life and higher risk of pulmonary exacerbations [3,4]. Pulmonary infections play an important role in neutrophil-related inflammation in the lung, which is associated with faster progression of SLD [5,6].
The impact of chest computed tomography and chest radiography on clinical management of cystic fibrosis lung disease
2020, Journal of Cystic FibrosisCitation Excerpt :Chest CT has been recognized as the gold standard to diagnose and monitor bronchiectasis and low attenuation regions, a combination of trapped air and/or hypoperfusion. They both correlate with clinically relevant markers of disease severity, such as the number of respiratory tract exacerbations, Pseudomonas infection and quality of life scores [6–12]. Furthermore, structural abnormalities on CT have been shown to precede decline in pulmonary function, suggesting CT can be a valuable tool for the early detection of developing lung damage [13,14].
Influence of Inspiratory/Expiratory CT Registration on Quantitative Air Trapping
2019, Academic RadiologyChest imaging in cystic fibrosis studies: What counts, and can be counted?
2017, Journal of Cystic Fibrosis
Funding/Support: This study was supported by grants from the Sophia Cystic Fibrosis Research Fund, the Dutch Cystic Fibrosis Foundation, the Italian Cystic Fibrosis Fund, and the Cystic Fibrosis Foundation.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).